Kadimastem (Israel) Probability of Future Stock Price Finishing Over 33.4

KDST Stock  ILA 51.30  3.40  6.22%   
Kadimastem's future price is the expected price of Kadimastem instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Kadimastem performance during a given time horizon utilizing its historical volatility. Check out Kadimastem Backtesting, Kadimastem Valuation, Kadimastem Correlation, Kadimastem Hype Analysis, Kadimastem Volatility, Kadimastem History as well as Kadimastem Performance.
  
Please specify Kadimastem's target price for which you would like Kadimastem odds to be computed.

Kadimastem Target Price Odds to finish over 33.4

The tendency of Kadimastem Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above  33.40  in 90 days
 51.30 90 days 33.40 
close to 99
Based on a normal probability distribution, the odds of Kadimastem to stay above  33.40  in 90 days from now is close to 99 (This Kadimastem probability density function shows the probability of Kadimastem Stock to fall within a particular range of prices over 90 days) . Probability of Kadimastem price to stay between  33.40  and its current price of 51.3 at the end of the 90-day period is about 1.9 .
Assuming the 90 days trading horizon Kadimastem has a beta of -1.82. This indicates as returns on its benchmark rise, returns on holding Kadimastem are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Kadimastem is expected to outperform its benchmark. Additionally Kadimastem has an alpha of 0.0586, implying that it can generate a 0.0586 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
   Kadimastem Price Density   
       Price  

Predictive Modules for Kadimastem

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Kadimastem. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kadimastem's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
46.6051.3056.00
Details
Intrinsic
Valuation
LowRealHigh
41.1645.8656.43
Details
Naive
Forecast
LowNextHigh
48.8053.5058.20
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
48.8655.8962.92
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Kadimastem. Your research has to be compared to or analyzed against Kadimastem's peers to derive any actionable benefits. When done correctly, Kadimastem's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Kadimastem.

Kadimastem Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Kadimastem is not an exception. The market had few large corrections towards the Kadimastem's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Kadimastem, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Kadimastem within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
0.06
β
Beta against NYSE Composite-1.82
σ
Overall volatility
2.87
Ir
Information ratio -0.07

Kadimastem Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Kadimastem for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Kadimastem can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Kadimastem generated a negative expected return over the last 90 days
Kadimastem has high historical volatility and very poor performance
The company has accumulated 12.96 M in total debt with debt to equity ratio (D/E) of 7.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kadimastem has a current ratio of 0.38, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kadimastem until it has trouble settling it off, either with new capital or with free cash flow. So, Kadimastem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kadimastem sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kadimastem to invest in growth at high rates of return. When we think about Kadimastem's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (26.27 M) with profit before overhead, payroll, taxes, and interest of 0.
Kadimastem has accumulated about 5.43 M in cash with (21.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Roughly 54.0% of Kadimastem outstanding shares are owned by corporate insiders

Kadimastem Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Kadimastem Stock often depends not only on the future outlook of the current and potential Kadimastem's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kadimastem's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding33.7 M

Kadimastem Technical Analysis

Kadimastem's future price can be derived by breaking down and analyzing its technical indicators over time. Kadimastem Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Kadimastem. In general, you should focus on analyzing Kadimastem Stock price patterns and their correlations with different microeconomic environments and drivers.

Kadimastem Predictive Forecast Models

Kadimastem's time-series forecasting models is one of many Kadimastem's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Kadimastem's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Kadimastem

Checking the ongoing alerts about Kadimastem for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Kadimastem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Kadimastem generated a negative expected return over the last 90 days
Kadimastem has high historical volatility and very poor performance
The company has accumulated 12.96 M in total debt with debt to equity ratio (D/E) of 7.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kadimastem has a current ratio of 0.38, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kadimastem until it has trouble settling it off, either with new capital or with free cash flow. So, Kadimastem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kadimastem sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kadimastem to invest in growth at high rates of return. When we think about Kadimastem's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (26.27 M) with profit before overhead, payroll, taxes, and interest of 0.
Kadimastem has accumulated about 5.43 M in cash with (21.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Roughly 54.0% of Kadimastem outstanding shares are owned by corporate insiders
Check out Kadimastem Backtesting, Kadimastem Valuation, Kadimastem Correlation, Kadimastem Hype Analysis, Kadimastem Volatility, Kadimastem History as well as Kadimastem Performance.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Kadimastem Stock analysis

When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Please note, there is a significant difference between Kadimastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kadimastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kadimastem's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.